A HIGH PROFILE REVIEW ON NEW ORAL CLOTTING FACTOR XA INHIBITOR: BETRIXABAN
Nikunj Patadiya* and Rajesh Dumpala
Venous thromboembolism is commonly defined as a situation in which blood clot forms in blood vessels. It has two types Deep vein thrombosis (clot became in leg, groin or arm) and pulmonary embolism (clot became in circulation, lodging in lungs). For the treatments of this condition number of medicines are used like unfractionated heparins, low molecular weight heparins(LMWH), warfarin, and vitamin K antagonists. They all agents have their own side effects and efficacy. Long term treatment causes pain, redness, irritation, bluish colored skin etc. For reduce side effects and improve efficacy the novel anticoagulants are required. New agents like enoxaparin, apixaban and rivaroxaban is use for the treatments of Venous thromboembolism but clinical trails shows higher risks of major bleeding. Betrixaben is approved by FDA in class of clotting factor Xa inhibitor. Betrixaban became first anticoagulant(by inhibit factor Xa) approved in the United States (US) for prophylaxis of venous thromboembolism extending away from hospitalization.[2,3] Its have unique pharmacokinetic properties, long half-life, low metabolism rate by cytochrome p450 and not metabolized by CYP3A4 system and less renal excretion. In this article, we review on its pharmacological effect, clinical trail study results, comparition with other anticoagulants, its side effects and use against Venous Thromboembolism and other pathological conditions.
Keywords: Betrixaban, venous thromboembolism, pharmacokinetics, clinical trails, adverse effects.
[Full Text Article]